INFLUENCE OF ASTHENIA ON THE PSYCHOLOGICAL WELL-BEING OF PATIENTS WITH TYPE 2 DIABETES IN AKTOBE
2025 жыл | Шығарылым: 5 | Беттер: 127-135
EXPERIENCES OF PRIMARY CARE PSYCHOLOGISTS IN IDENTIFYING AND MANAGING GAMBLING DISORDER IN ALMATY AND ASTANA, KAZAKHSTAN: CHALLENGES AND IMPLICATIONS FOR PRACTICE
2025 жыл | Шығарылым: 5 | Беттер: 136-142
THE RESULTS OF PSYCHOMETRIC SCREENING TO STUDY THE PRESUICIDAL ATTITUDES OF YOUTH AND YOUNG ADULTS IN KAZAKHSTAN
2025 жыл | Шығарылым: 5 | Беттер: 143-152
EFFICACY AND SAFETY OF MOMETASONE FUROATE IN CHILDREN WITH ATOPIC DERMATITIS IN KAZAKHSTAN
2025 жыл | Шығарылым: 5 | Беттер: 153-159
RECTAL CANCER IN KAZAKHSTAN, 2005–2024: COMPONENT ANALYSIS OF INCIDENCE TRENDS IN THE CONTEXT OF SCREENING AND COVID-19
2025 жыл | Шығарылым: 5 | Беттер: 160-168
MAPPING THE RESEARCH LANDSCAPE: IONIZING RADIATION-INDUCED OXIDATIVE STRESS AND INFLAMMATION IN THE BRAIN – A BIBLIOMETRIC ANALYSIS
2025 жыл | Шығарылым: 5 | Беттер: 169-182
ASSOCIATION BETWEEN EXPOSURE TO IONIZING RADIATION AND THE DEVELOPMENT OF CARDIOVASCULAR DISEASES: A LITERATURE REVIEW
2025 жыл | Шығарылым: 5 | Беттер: 183-190
ADVANCES IN POTENTIAL BIOMARKERS FOR RHEUMATOID ARTHRITIS: SYSTEMATIC REVIEW
2025 жыл | Шығарылым: 5 | Беттер: 191-202
RISK FACTORS AND PREVALENCE OF URINARY INCONTINENCE AMONG WOMEN IN FOREIGN COUNTRIES. LITERATURE REVIEW
2025 жыл | Шығарылым: 5 | Беттер: 203-213
THE IMPACT OF SCREEN TIME ON THE HEALTH OF THE MUSCULOSKELETAL SYSTEM IN CHILDREN AND ADOLESCENTS: A SYSTEMATIC REVIEW
2025 жыл | Шығарылым: 5 | Беттер: 214-222
PREVENTION AND EVALUATION OF INFORMATION KNOWING FOR RISK FACTORS OF INSULTS
The article presents the data about insults prevention, epidemiology and information knowing of population.
Толығырақ
2014 жыл | Шығарылым: 1 | Беттер: 67-69
THE DIFFERENTIATED APPROACH TO AN ANEMIA SYNDROME IN CLINICAL PRACTICE
Anemia is the most common blood disorder. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of red blood cells and underlying etiologic mechanisms. Anemia goes undetermined in many people, and symptoms can be minor or vague. The signs and symptoms can be related to the anemia itself, or the underlying causes. This article is about the main principles of diagnosis of anemia in clinical practice. We hope that this information will help to diagnose the different types of anemia in daily clinical pr...
Толығырақ
2014 жыл | Шығарылым: 1 | Беттер: 61-64
FROMILID UNO IN TREATMENT ACUTE PNEUMONIA
We observed 60 patients with acute community - acquired pneumonia, aged 32 to 67 years. The median age was 46,2 years. The first group consisted of 30patients who received the drug with antibacterial purpose Fromilid UNO in a dose of 500 mg1 h 2p per day for 10 days. The second group consisted of 30 patients received cefazolin1,0х2r/ m with in 10 days. Under the influence of the rap noted positive dynamics of both groups, but more pronounced in the first group. Fromilid UNO in treatment acute pneumonia demonstrated high clinical antibacterial effects.
Толығырақ
2014 жыл | Шығарылым: 1 | Беттер: 59-61
ПРОБЛЕМА АНТИБИОТИКОРЕЗИСТЕНТНОСТИ ОСНОВНЫХ ВОЗБУДИТЕЛЕЙ ВНЕБОЛЬНИЧНОЙ ПНЕВМОНИИ И ПУТИ ЕЕ ПРЕОДОЛЕНИЯ
In the paper we have presented results of bacteriological investigation of sputum and analysis of sensitivity for the main inducers of community acquired pneumonia in the patients of pulmonology department. It was described the causes of antibiotic resistance and modern methods of combination antibiotic treatment of community-acquired pneumonia.
Толығырақ
2014 жыл | Шығарылым: 1 | Беттер: 57-59
EFFICIENCY OF APPLICATION MACROLIDES (FROMILID UNO) AT INFECTIONS OF THE UPPER AND LOWER RESPIRATORY TRACTS
The studies found that: Еxperience of clinical practice suggests that Fromilid UNO (clarithromycin) occupies an important place in the treatment of acute and chronic infections of the upper and lower respiratory tracts and increases the relevance of its application to obtain new information about the effects of the antibacterial agent. Validated high efficacy and safety Fromilid UNO in patients with acute and chronic infectious and inflammatory diseases of the upper and lower respiratory tract. Dosing of the drug once per day creates high compliance, minimizing side effects.
Толығырақ
2014 жыл | Шығарылым: 1 | Беттер: 55-57